COVID-19
Conditions
Interventions
None
Sponsors
ISA Pharmaceuticals B.V.
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for both recovered COVID-19 patients and healthy participants 1. Participant must sign the study informed consent form prior to any study-mandated procedure indicating that he or she understands the purpose, procedures and potential risks, and is willing to participate in the study; 2. Participant is male or female and between 18 and 65 years of age, inclusive, at the time of enrollment; 3. Participant is willing and able to complete the study procedures; 4. Participant has a primary care physician at the time of enrollment; 5. Participant is not taking any immunosuppressive medication or other immunomodulating agents (including investigational drugs) for at least 3 weeks prior to study blood sampling. Inclusion criteria for recovered COVID-19 patients only 1. Participant reports a previous positive diagnostic test result for SARS-CoV-2 infection (serological testing or viral RNA detection by PCR testing); 2. Participant had clinical symptoms of COVID-19 (including, but not limited to: cough, fever, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia). The diagnosis of COVID-19 must be the most plausible cause of the reported symptoms, as deemed by the study physician; 3. Participant has recovered from COVID-19 for at least three weeks prior to study blood sampling (residual symptoms such as, but not limited to, fatigue and reduced exercise tolerance - that would not jeopardize study endpoints - are allowed at the investigator’s discretion). Inclusion criteria for healthy participants only 1. Participant is generally healthy in the investigator’s clinical judgment, as determined by medical history evaluation, including no clinically significant disorder, condition, infection or disease that would interfere with the study evaluation, procedures or completion.
Exclusion criteria
Exclusion criteria: Exclusion criteria for both recovered COVID-19 patients and healthy participants 1. Participant with a whole blood donation or loss of >500 ml within 21 days before study blood sampling; 2. Any known factor, condition, or disease that might interfere with compliance, study conduct or interpretation of the results, as deemed by the investigator. Exclusion criteria for healthy participants only 1. Participant reports a previous positive diagnostic test result for SARS-CoV-2 infection (serological testing or viral RNA detection by PCR testing); 2. Participant developed clinically overt symptoms of COVID-19 following close contact with a proven SARS-CoV-2 positive patient, but was not tested (e.g. due to limited test capacity and regulations at that time); 3. Participant who is currently working, or has worked in an occupation with a high risk of exposure to SARS-CoV-2 (e.g. health care worker).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Memory T cell response as assessed by interferon-? enzyme-linked immune absorbent spot (ELISpot) assay and/or enzyme-linked immunosorbent assay (ELISA) and intracellular cytokine staining (ICS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum IgG antibodies as measured by ELISA | — |
Contacts
Public ContactI.M.C. de Visser-Kamerling
Centre for Human Drug Research
Outcome results
None listed